Biopharma company GSK (LSE: GSK) (NYSE: GSK) announced on Monday that it has secured Fast Track designation from the US FDA for bepirovirsen, an investigational antisense oligonucleotide (ASO) targeting chronic hepatitis B (CHB).
The designation expedites drug development for serious conditions with unmet medical needs. Bepirovirsen's potential was supported by phase IIb trials B-Clear and B-Sure, with ongoing phase III program B-Well.
CHB affects nearly 300 million people globally, with current treatments offering a less than 2-8% functional cure rate.
Bepirovirsen is in phase III development, showing promise for a clinically meaningful functional cure response when combined with oral nucleoside/nucleotide analogues.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member